BMY vs GERN: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
BMY is the larger of the two ($133.41B market cap): the incumbent the market prices for continued execution (10.10x forward earnings, beta 0.23). GERN is the smaller challenger ($827.56M), actually pricier on forward earnings (21.50x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BMY vs GERN: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BMY | GERN | What it tells you |
|---|---|---|---|
| Market cap | $133.41B | $827.56M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 10.10 | 21.50 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.23 | 0.60 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 98% of range | 26% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.98 | 3.61 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: BMY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how BMY and GERN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and GERN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and GERN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Bristol Myers Squibb (BMY) do?
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is navigating a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.
What does Geron Corporation (GERN) do?
Geron Corporation is a commercial-stage biopharmaceutical company whose entire business today rests on Rytelo (imetelstat), a first-in-class telomerase inhibitor. The FDA approved Rytelo in June 2024 for adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia and have not responded to, or are ineligible for, erythropoiesis-stimulating agents. In March 2025 the European Commission approved it across the EU and EEA for non-del(5q) lower-risk MDS. The approvals rest on the IMerge Phase 3 trial, which showed Rytelo reduced patients' need for red blood cell transfusions versus placebo. Geron reported roughly $184 million of Rytelo net revenue in 2025 and has guided to about $220 million to $240 million for 2026, with two consecutive quarters of demand growth reported through Q1 2026.
BMY vs GERN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BMY drivers: New product portfolio ramp; Oncology and immunology depth.
- GERN drivers: Rytelo commercial ramp in lower-risk MDS; Myelofibrosis expansion via IMpactMF.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For GERN, the dominant risk is single-product concentration: with essentially all revenue from one drug, any slowdown in the Rytelo launch, reimbursement pushback, or competitive pressure hits the whole company.
BMY or GERN: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; GERN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and GERN guides.
BMY vs GERN: the full fundamentals
BMY. Bristol Myers tends to trade at a low forward earnings multiple relative to large-cap pharma peers, reflecting market skepticism about its ability to replace patent-cliff revenue. The high dividend yield and strong free cash flow are the bull-case anchors, while the depressed valuation reflects the bear case that legacy declines outrun newer products.
GERN. These figures are approximate and tied to the July 2026 asOf date; verify live numbers and current guidance before making any decision. For a commercial-stage biotech like Geron, traditional earnings multiples mean little because the company is only just approaching profitability. What matters more is the pace of Rytelo revenue growth, cash runway, and the outcome of the IMpactMF myelofibrosis trial. None of this is investment advice.
Headline figures (approximate, early 2026): BMY shows revenue (ttm) ~$48 billion, operating margin ~20% (varies with acquisition charges), net income (ttm) volatile, pressured by large acquisition write-offs, dividend yield ~4-5%; GERN shows rytelo revenue (2025) About $184 million, the first roughly full year of the US launch, 2026 revenue guidance Roughly $220 million to $240 million, reflecting continued launch ramp, q1 2026 revenue About $51.8 million, reported up sequentially with demand growth, profitability Still around breakeven: reported a small net loss in Q1 2026 as launch and trial spending remain high.
The bottom line: BMY vs GERN
BMY and GERN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and GERN exposure against your real portfolio. It is not an investment adviser.
Wondering how BMY or GERN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Bristol Myers Squibb with AI
Connect the broker you already use and ask Walnut's AI how BMY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between BMY and GERN?
+
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. Geron Corporation is a commercial-stage biopharmaceutical company whose entire business today rests on Rytelo (imetelstat), a first-in-class telomerase inhibitor. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BMY or GERN the better stock?
+
Neither is universally better. BMY is the larger incumbent; GERN is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BMY or GERN?
+
On forward P/E (as of August 2026), BMY trades at 10.10x and GERN at 21.50x, so BMY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BMY and GERN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BMY vs GERN?
+
BMY: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook. High debt from dealmaking and litigation exposure add further uncertainty. GERN: The dominant risk is single-product concentration: with essentially all revenue from one drug, any slowdown in the Rytelo launch, reimbursement pushback, or competitive pressure hits the whole company. Competition is real, as many physicians favor Reblozyl (luspatercept) frontline and reserve imetelstat for select patients, which caps the addressable pool. The IMpactMF myelofibrosis readout is a binary event that could sharply move the stock in either direction, and clinical trials can fail. Rytelo carries class-typical safety considerations, including cytopenias, that affect prescribing. As an unprofitable or barely profitable biotech, Geron may need to raise capital, risking dilution, and small-cap biotech stocks are historically volatile and sensitive to sentiment and single news events.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BMY or GERN; figures are approximate and dated (as of August 2026). Verify current data before investing.